CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION IS BOTH (1) NOT MATERIAL AND (2) THE TYPE THAT THE REGISTRANT CUSTOMARILY TREATS AS PRIVATE OR CONFIDENTIAL. SUPPLY AND...Supply and Non-Exclusive License Agreement • March 29th, 2023 • Angion Biomedica Corp. • Pharmaceutical preparations • New York
This Supply and Non-Exclusive License Agreement (“Agreement”), made as of May 11, 2022 (the “Effective Date”), is by and between Regeneron Pharmaceuticals, Inc. (“Regeneron”), having a place of business at 777 Old Saw Mill River Road, Tarrytown, NY 10591-6707 and Elicio Therapeutics, Inc. (“Sponsor”), having a place of business at 451 D Street, Suite 501, Boston, MA 02210. Regeneron and Sponsor are each referred to herein individually as “Party” and collectively “Parties.”
EMPLOYMENT AGREEMENTEmployment Agreement • March 29th, 2023 • Angion Biomedica Corp. • Pharmaceutical preparations • Massachusetts
This Employment Agreement (the “Agreement”) is made and entered into as of November 15, 2018, by and between Robert Connelly (the “Executive”) and Vedantra Pharmaceuticals, Inc., a Delaware corporation (the “Company”).
CONSULTING AGREEMENTConsulting Agreement • March 29th, 2023 • Angion Biomedica Corp. • Pharmaceutical preparations • Massachusetts
This Consulting Agreement (the “Agreement”) is made effective as of March 13, 2013 (the “Effective Date”), by and between Vedantra Pharmaceuticals Inc., a Delaware corporation, with its principal place of business being One Kendall Square, Building 1400 West, Suite 14303 Cambridge, MA. 02139 (the “Company”) and Danforth Advisors, LLC, a Massachusetts limited liability corporation, with its principal place of business being 91 Middle Road, Southborough, MA 01772 (“Danforth”). The Company and Danforth are herein sometimes referred to individually as a “Party” and collectively as the “Parties.”
January 12, 2021 Annette Matthies Cocoa Beach, FL 32931 Dear Annette,Angion Biomedica Corp. • March 29th, 2023 • Pharmaceutical preparations • Massachusetts
We are pleased to extend you this offer of employment to become Chief Business Officer (CBO) with Elicio Therapeutics, Inc. (“Elicio” or the “Company”). This offer may be accepted by countersigning where indicated at the end of this letter agreement. We are excited about the contributions that we know you will make to the success of the Company and would like your employment to commence on January 13th, 2021 (the actual date on which your employment commences is referred to below as the “Start Date”).
MASSACHUSETTS INSTITUTE OF TECHNOLOGY AND VEDANTRA PHARMACEUTICALS, INC. EXCLUSIVE PATENT LICENSE AGREEMENTPatent License Agreement • March 29th, 2023 • Angion Biomedica Corp. • Pharmaceutical preparations • Massachusetts
This AGREEMENT (as later defined herein), effective as of the date set forth above the signatures of the parties below (the “EFFECTIVE DATE”), is between the Massachusetts Institute of Technology (“M.I.T.”), a Massachusetts corporation, with a principal office at 77 Massachusetts Avenue, Cambridge, MA 02139-4307 and Vedantra Pharmaceuticals. Inc. (“COMPANY”), a Delaware corporation, with a principal place of business at One Kendall Square, Building 1400 West, Suite 14303, Cambridge, MA 02139.
